Published As:
DE10161738
Title:
New fusion protein, useful for selective treatment of T cell tumors, comprises T cell ligand linked to cytostatic or immunostimulating component
Value Drivers by Geography
Seller defined
PCT Application Office Action Grant
Rest of the World
Germany
Patent PDF
Figure
New fusion protein, useful for selective treatment of T cell tumors, comprises T cell ligand linked to cytostatic or immunostimulating component
Priority Date
15
Dec
01
Share
Abstract:
Fusion proteins able to target (malignant) T cells and to destruct them selectively and effectively especially by affecting their microtubules.
Claim 1:
Fusion proteins, wherein they comprise at least one component selected from (T cell-specific ligand) CD58, CD72, CD29 and at least one second component selected from GTPase, GTP hydrolase, endotoxin of Vibrio cholera, protease subtilisin, microtubule-binding region of gephyrin, Tau or MID-1 protein.